top of page

Syncromune's AACR late-breaker of phase 1 data for the SYNC-T immunotherapy drug-device combo in mCRPC

CEO Eamonn Hobbs describes early responses being seen in the trial and explains how this needle-like device and combination of immunotherapy drugs works.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page